Torrent Pharmaceuticals Limited

Equities

TORNTPHARM

INE685A01028

Pharmaceuticals

Delayed Bombay S.E. 06:00:52 2024-03-28 am EDT 5-day change 1st Jan Change
2,601 INR +1.45% Intraday chart for Torrent Pharmaceuticals Limited +1.76% +12.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director CI
Nomura Adjusts Torrent Pharmaceuticals' Price Target to INR2,975 From INR2,156, Keeps at Buy MT
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,930 From INR2,750, Keeps at Buy MT
Torrent Pharmaceuticals Posts Gains in Fiscal Q3 Consolidated Net Profit MT
Torrent Pharmaceuticals' Consolidated Profit in Fiscal Q3 MT
Transcript : Torrent Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 02, 2024
India's Torrent Pharma posts higher Q3 profit on strong domestic demand RE
Torrent Pharmaceuticals Limited Announces Interim Dividend, Payable on or around 23 February, 2024 CI
Torrent Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO RE
Torrent Pharmaceuticals Forms New Wholly-Owned Arm in Colombia MT
Torrent Pharmaceuticals' Oral Oncology Plant Gets Fives Observations from US FDA MT
Zydus Lifesciences Limited and Torrent Pharmaceuticals Limited Enter into Licensing and Supply Agreement to Co-Market, Saroglitazar Mg CI
Nomura Adjusts Torrent Pharmaceuticals Price Target to INR2,156 From INR2,199, Keeps at Buy MT
Torrent Pharmaceuticals' Consolidated Profit Climbs in Fiscal Q2; EPS, Revenue Meet Estimates MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,040 From INR1,950, Keeps at Hold MT
Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences CI
Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative CI
India's Torrent Pharma posts Q2 profit rise on strong demand RE
Transcript : Torrent Pharmaceuticals Limited, Q2 2024 Earnings Call, Oct 23, 2023
Torrent Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
India's Glenmark Life Sciences posts Q2 profit rise on API boost RE
Family Rift Clouds $7 Billion Sale of Cipla CI
Torrent Pharmaceuticals Limited Announces Resignation of Hitesh Maheshwari, Executive Director (Product Development), Designated as Senior Management Personnel CI
Chart Torrent Pharmaceuticals Limited
More charts
Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
2,601 INR
Average target price
2,713 INR
Spread / Average Target
+4.31%
Consensus